Buy Sofosbuvir/velpatasvir 400mg/100mg – Epclusa


Treatment duration for treatment-naïve and treatment-experienced liver transplant recipients

  • Without cirrhosis or with compensated cirrhosis (Child-Pugh A): Sofosbuvir/velpatasvir for 12 weeks
  • With decompensated cirrhosis (Child-Pugh B or C): Sofosbuvir/velpatasvir plus ribavirin for 12 weeks
  • Weight-based ribavirin dose
    • <75 kg: 1000 mg/day PO divided BID
    • ≥75 kg: 1200 mg/day PO divided BID
    • Modify ribavirin starting dose and on-treatment dosage based on hemoglobin and creatinine clearance


Epclusa is Indicated for chronic hepatitis C virus (HCV) infection in adults with HCV genotypes 1, 2, 3, 4, 5, and 6 without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis for use in combination with ribavirin

1 tablet (400 mg sofosbuvir/100 mg velpatasvir) per day

Epclusa (Sofosbuvir 400 mg + Velpatasvir 100 mg) is currently the most effective treatment for Hepatitis C genotype 3. Epclusa will also effectively treat all other genotypes of Hepatitis C.